Tracking health for people with blastic plasmacytoid dendritic cell neoplasm
Treatments studied
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This study follows people with a rare blood cancer called BPDCN who are starting or recently started a medicine called Elzonris (tagraxofusp). It collects health information to see how the treatment works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with BPDCN (blastic plasmacytoid dendritic cell neoplasm), a rare blood cancer.
- You are starting treatment with the drug Elzonris (tagraxofusp) now or have started it within the past 6 months.
- You are not taking part in another study or registry that reports on your BPDCN treatment.
- You are not currently in an interventional clinical trial (a trial that tests a treatment).
- You do not have known allergies to any components of tagraxofusp.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
This study looks back at the health records of people who were treated for BPDCN (a rare blood cancer) with chemotherapy as their first treatment. The goal is to learn more about how the disease progresses and how well treatments work in the real world. If you meet the criteria, your past medical data may be included.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This Phase 2 trial tests venetoclax combined with chemotherapy to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). It may help shrink BPDCN and control the disease, whether you’re newly diagnosed or the cancer has come back.
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
Hear when a new Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.